Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In Japan, skincare products such as "Rohto V5," "Hada Labo" and "CareCera," as well as eye drops for younger consumers and premium eye drops, performed well. Overseas, ユーヤンサン・インターナショナル, China, Vietnam and Malaysia, among others, performed well. Operating income increased due to the effect of higher sales, while the cost ratio improved as a result of price revisions for "Hada Labo" and a higher in-house production ratio. Ordinary income and interim net income attributable to owners of the parent declined due to a year-on-year decrease following the one-time dividend income recorded in the previous fiscal year.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥179,006 million (YoY +9.0%) |
| Operating profit | ¥20,953 million (YoY +8.5%) |
| Ordinary income | ¥21,845 million (YoY -11.2%) |
| Profit attributable to owners of the parent | ¥16,498 million (YoY -6.5%) |
| Net income per share | ¥73.08 |
| Equity ratio | End of the current fiscal period 62.9 / End of previous period 62.1 |
| Total assets | ¥501,021 million |
| Net assets | ¥334,796 million |
| Cash flows from operating activities | ¥20,248 million |
| Cash flows from investing activities | ¥-10,529 million |
| Cash flows from financing activities | ¥-15,549 million |
| Cash and cash equivalents at end of period | ¥78,814 million |
| Full-year earnings forecast | Net Sales ¥372,300 million (YoY +8.3%) / Operating profit ¥45,000 million (YoY +9.4%) / Ordinary income ¥47,400 million (YoY -1.2%) / Net income ¥35,200 million (YoY +2.8%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥46 → ¥50 |
| Segment revenue | Japan ¥86,070 million (YoY +3.0%), United States ¥10,344 million (YoY +2.3%), Europe ¥13,351 million (YoY +15.7%), Asia ¥67,160 million (YoY +17.1%) |
| Segment profit | Japan ¥11,943 million (YoY +8.0%), United States ¥-403 million, Europe ¥717 million (YoY +218.5%), Asia ¥8,025 million (YoY +12.4%) |
| Depreciation and amortization | ¥8,020 million |
| Impairment loss | Not applicable |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥1,456 million / Extraordinary loss Not applicable |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 2 companies (マジック・コッド and 1 other company) / Excluded 0 companies |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 236,178,310 shares |
| Treasury Shares at Period-End | 11,252,618 shares |
| Factors Behind Changes in Business Performance | In Japan, skincare products such as "Rohto V5," "Hada Labo" and "CareCera," as well as eye drops for younger consumers and premium eye drops, performed well. Overseas, ユーヤンサン・インターナショナル, China, Vietnam and Malaysia, among others, performed well. Operating income increased due to the effect of higher sales, while the cost ratio improved as a result of price revisions for "Hada Labo" and a higher in-house production ratio. Ordinary income and interim net income attributable to owners of the parent declined due to a year-on-year decrease following the one-time dividend income recorded in the previous fiscal year. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased as "Rohto V5," "Hada Labo" and "CareCera," among others, performed well in Japan, while the overseas segment performed well, particularly at ユーヤンサン・インターナショナル and in China. Operating income increased due to the effect of higher sales, as well as an improvement in the cost ratio resulting from price revisions for "Hada Labo" and a higher in-house production ratio. Ordinary income and interim net income attributable to owners of the parent declined due to a year-on-year decrease following the one-time dividend income recorded in the previous fiscal year.